Skip to main content

Advertisement

SpringerLink
Log in

Erfolg für eine neue Generation von Basistherapeutika

Der Janus-Kinase-Inhibitor Baricitinib bei rheumatoider Arthritis

Success for a new generation of disease-modifying antirheumatic drugs

The Janus kinase inhibitor baricitinib in rheumatoid arthritis

  • Klinische Studien kurzgefasst
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Burmester GR, Blanco R, Charles-Schoeman C et al (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381:451–460

    Article  CAS  PubMed  Google Scholar 

  2. Keystone EC, Taylor PC, Drescher E et al (2015) Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 74:333–340

    Article  CAS  PubMed  Google Scholar 

  3. Shi JG, Chen X, Lee F et al (2014) The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol 54:1354–1361

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department für Innere Medizin, Klinik für Innere Medizin II, Universitätsklinikum Halle, Ernst-Grube-Str. 40, 06097, Halle (Saale), Deutschland

    G. Keyßer

Authors
  1. G. Keyßer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Keyßer.

Ethics declarations

Interessenkonflikt

G. Keyßer gibt an, dass er 2016 einmalig ein Referentenhonorar der Firma Abbvie erhalten hat.

Additional information

Redaktion

C. Fiehn, Baden Baden

B. Hellmich, Kirchheim-Teck

I. Kötter, Hamburg

K. Krüger, München

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keyßer, G. Erfolg für eine neue Generation von Basistherapeutika. Z Rheumatol 76, 461–462 (2017). https://doi.org/10.1007/s00393-017-0307-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-017-0307-3

Search

Navigation